US 11,963,969 B2
Method for prevention or treatment of amyotrophic lateral sclerosis by administering gastrodin
Chia-Yu Chang, Hualien (TW); Shinn-Zong Lin, Hualien (TW); Hsiao-Chien Ting, Hualien (TW); Hui-I Yang, Hualien (TW); Horng-Jyh Harn, Hualien (TW); Hong-Lin Su, Hualien (TW); Ching-Ann Liu, Hualien (TW); Yu-Shuan Chen, Hualien (TW); Tzyy-Wen Chiou, Hualien (TW); and Tsung-Jung Ho, Hualien (TW)
Assigned to BUDDHIST TZU CHI MEDICAL FOUNDATION, Hualien (TW)
Filed by BUDDHIST TZU CHI MEDICAL FOUNDATION, Hualien (TW)
Filed on Sep. 16, 2022, as Appl. No. 17/932,781.
Claims priority of application No. 110134908 (TW), filed on Sep. 17, 2021.
Prior Publication US 2023/0263813 A1, Aug. 24, 2023
Int. Cl. A61K 31/7034 (2006.01); A61K 9/00 (2006.01); A61K 31/428 (2006.01); A61P 25/28 (2006.01)
CPC A61K 31/7034 (2013.01) [A61K 9/0019 (2013.01); A61K 31/428 (2013.01); A61P 25/28 (2018.01)] 9 Claims
 
1. A method for relieving amyotrophic lateral sclerosis in a subject in need thereof, comprising:
administering, to the subject, a pharmaceutical composition comprising a therapeutically effective dose of gastrodin and a pharmaceutically acceptable carrier, wherein the subject has at least one disease selected from the group consisting of hereditary amyotrophic lateral sclerosis and sporadic amyotrophic lateral sclerosis wherein the gastrodin has at least one effect observed in an analysis on the subject selected from the group consisting of improvement in axon growth of neurons, decrease in accumulation of neurofilaments, and recovery of nerve electrophysiological function, as compared to those of a subject that has not been administered with the therapeutically effective dose of gastrodin.